LDS/Medical Tests/Levorphanol, Urine

Levorphanol, Urine

Levorphanol is the l-isomer of 3-hydroxy-N-methylmorphinan. It is a synthetic opioid agonist with properties similar to morphine; however, levorphanol is more potent and the analgesic effect lasts longer than morphine. Typical routes of administration are oral and subcutaneous. Levorphanol is metabolized primarily to norlevorphanol and its glucuronide conjugates, and is excreted in the urine. The half-life of levorphanol is 11-16 hours.

Animal studies suggest that 97% of a dose is eliminated within four days, with 60% appearing in the urine. Actual elimination depends on factors such as drug formulation, dose, dose frequency, clinical status and pharmacokinetics of the individual patient.

Common side effects: respiratory depression, sedation, nausea, vomiting, dizziness, miosis, constipation, urinary retention. Levorphanol can also contribute to the following effects: euphoria, sedation, mental clouding, amnesia, hostility, irritability, pruritis, and vivid or disturbing dreams. Tolerance develops rapidly and can be addictive. Overdose effects include respiratory collapse, seizure, coma, and possible death.

Levorphanol can be analyzed in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A positive result indicates the presence of Levorphanol and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/ml
Toxic level: >200 ng/ml
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS or LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). A pre-analytical hydrolysis reaction to liberate the glucuronide conjugates may improve detection. Commercial immunoassays specific to levorphanol are not available. The d-isomer of levorphanol is dextromethorphan. As such, assays that cannot distinguish between stereoisomers may be at risk for false positive results in the presence of dextromethorphan.

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Supportive testing such as liver profile, kidney profile, comprehensive metabolic panel, CBC (if overdose), and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Forster City, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.